Vestibular schwannomas

Treatment with bevacizumab

Daniel M.S. Raper, Ricardo J Komotar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.

Original languageEnglish (US)
Title of host publicationTumors of the Central Nervous System, Volume 7
Subtitle of host publicationMeningiomas and Schwannomas
PublisherSpringer Netherlands
Pages335-339
Number of pages5
ISBN (Electronic)9789400728943
ISBN (Print)9789400728936
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Acoustic Neuroma
Vestibular Nerve
Cranial Nerve Diseases
Cranial Nerves
Neurilemmoma
Therapeutics
Hearing Loss
Vascular Endothelial Growth Factor A
Radiotherapy
Bevacizumab
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raper, D. M. S., & Komotar, R. J. (2012). Vestibular schwannomas: Treatment with bevacizumab. In Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas (pp. 335-339). Springer Netherlands. https://doi.org/10.1007/978-94-007-2894-3_36

Vestibular schwannomas : Treatment with bevacizumab. / Raper, Daniel M.S.; Komotar, Ricardo J.

Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas. Springer Netherlands, 2012. p. 335-339.

Research output: Chapter in Book/Report/Conference proceedingChapter

Raper, DMS & Komotar, RJ 2012, Vestibular schwannomas: Treatment with bevacizumab. in Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas. Springer Netherlands, pp. 335-339. https://doi.org/10.1007/978-94-007-2894-3_36
Raper DMS, Komotar RJ. Vestibular schwannomas: Treatment with bevacizumab. In Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas. Springer Netherlands. 2012. p. 335-339 https://doi.org/10.1007/978-94-007-2894-3_36
Raper, Daniel M.S. ; Komotar, Ricardo J. / Vestibular schwannomas : Treatment with bevacizumab. Tumors of the Central Nervous System, Volume 7: Meningiomas and Schwannomas. Springer Netherlands, 2012. pp. 335-339
@inbook{0e56e3d48c7946eca9b92794b910face,
title = "Vestibular schwannomas: Treatment with bevacizumab",
abstract = "Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.",
author = "Raper, {Daniel M.S.} and Komotar, {Ricardo J}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-94-007-2894-3_36",
language = "English (US)",
isbn = "9789400728936",
pages = "335--339",
booktitle = "Tumors of the Central Nervous System, Volume 7",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - Vestibular schwannomas

T2 - Treatment with bevacizumab

AU - Raper, Daniel M.S.

AU - Komotar, Ricardo J

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.

AB - Currently there are no established medical treatments for vestibular schwannoma. Surgery may result in vestibular nerve damage and hearing loss, while radiotherapy can lead to cranial nerve neuropathy and increase the risk of secondary malignancy. Due to its effect on the VEGF pathway, which has been shown to be dysregulated in vestibular schwannomas, bevacizumab has been investigated as a potentially efficacious medical therapy for schwannomas that are unsuitable for surgical resection. Though the place of this treatment in the paradigm of vestibular schwannoma therapy remains to be fully understood, it represents a promising advance for a complex disease for which few satisfactory options currently exist.

UR - http://www.scopus.com/inward/record.url?scp=85030983648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030983648&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-2894-3_36

DO - 10.1007/978-94-007-2894-3_36

M3 - Chapter

SN - 9789400728936

SP - 335

EP - 339

BT - Tumors of the Central Nervous System, Volume 7

PB - Springer Netherlands

ER -